- Home
- GHRS vs ORGO Comparison
GHRS vs ORGO Comparison
Compare GHRS & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- ORGO
- Stock Information
- Founded
- GHRS 2018
- ORGO 1985
- Country
- GHRS Ireland
- ORGO United States
- Employees
- GHRS N/A
- ORGO N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- GHRS Health Care
- ORGO Health Care
- Exchange
- GHRS Nasdaq
- ORGO Nasdaq
- Market Cap
- GHRS 583.1M
- ORGO 533.9M
- IPO Year
- GHRS 2021
- ORGO N/A
- Fundamental
- Price
- GHRS $12.03
- ORGO $2.74
- Analyst Decision
- GHRS Strong Buy
- ORGO Buy
- Analyst Count
- GHRS 8
- ORGO 2
- Target Price
- GHRS $30.63
- ORGO $5.50
- AVG Volume (30 Days)
- GHRS 149.3K
- ORGO 1.7M
- Earning Date
- GHRS 05-08-2025
- ORGO 05-08-2025
- Dividend Yield
- GHRS N/A
- ORGO N/A
- EPS Growth
- GHRS N/A
- ORGO N/A
- EPS
- GHRS N/A
- ORGO N/A
- Revenue
- GHRS N/A
- ORGO $458,760,000.00
- Revenue This Year
- GHRS N/A
- ORGO $2.73
- Revenue Next Year
- GHRS N/A
- ORGO $12.28
- P/E Ratio
- GHRS N/A
- ORGO N/A
- Revenue Growth
- GHRS N/A
- ORGO 5.35
- 52 Week Low
- GHRS $6.00
- ORGO $2.28
- 52 Week High
- GHRS $20.50
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- GHRS 58.82
- ORGO 30.42
- Support Level
- GHRS $10.66
- ORGO $2.96
- Resistance Level
- GHRS $13.00
- ORGO $3.28
- Average True Range (ATR)
- GHRS 0.96
- ORGO 0.18
- MACD
- GHRS 0.12
- ORGO -0.05
- Stochastic Oscillator
- GHRS 67.84
- ORGO 2.52
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.